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Protein loss induced by complement activation during
peritoneal dialysis
FREDERICK N. MILLER, DALE E. HAMMERSCHMIDT, GARY L. ANDERSON, and JIM N. MOORE
Department of Physiology, University of Louisville, Louisville, Kentucky; Department of Medicine, University of Minnesota, Minneapolis,
Minnesota; and Departments of Large Animal Medicine and Physiology-Pharmacology, University of Georgia, Athens, Georgia
Protein loss induced by complement activation during peritoneal dialy-
sis. A variable loss of macromolecules during peritoneal dialysis has
been noted in both humans and experimental animals. We investigated
the potential role of the complement system for inducing protein loss
during peritoneal dialysis, both to shed light on clinical variability of
protein loss and to develop a model for quantitatively studying comple-
ment-induced microvascular protein leakage. Rats received intra-arteri-
al injections of a fluorescent dye conjugated to rat serum albumin and
underwent a 3.5-hr series of 15-mm peritoneal dialysis exchanges, After
the control exchanges, rats received either intra-arterial zymosan-
activated rat serum, saline, unactivated rat serum, or endotoxin; other
rats received an intraperitoneal injection of endotoxin, histamine,
phenylephrine, or nitroprusside. The drainage volume from each ex-
change was measured, and the concentrations of labeled albumin, total
protein, and urea were determined by spectroscopy. Zymosan-activat-
ed rat serum and endotoxin injections (both intraperitoneal and intra-
arterial), each of which may activate the alternative pathway of
complement, produced a dramatic increase in dialysate protein concen-
trations. In addition, histamine, which is a vasodilator but which may
also be involved as a mediator of the activated complement system
and/or endotoxemia, also produced an increase in dialysate protein
concentrations. On the other hand, drugs which may alter peritoneal
blood flow such as the vasodilator nitroprusside or the vasoconstrictor
phenylephrine, did not affect dialysate protein concentrations. These
data suggest that activation of the alternative pathway of complement
may cause variation in protein loss during peritoneal dialysis and that in
some situations, pharmacological control of this system could be an
important therapeutic consideration.
Perte protéinique indulte par activation du complement pendant Ia
dialyse péritonéale. Une perte variable de macromolecules pendant la
dialyse pCritoneale a etC notCe aussi bien chez l'homme que chez des
animaux expCrimentaux. Nous avons CtudiC Ic role potentiel du sys-
tème du complCment dans l'induction d'une perte protCinique pendant
la dialyse pCritonCale, a Ia fois pour apporter quelque lumiCre sur la
variabilitC clinique de Ia perte protCinique, et pour dCvelopper un
modèle pour Ctudier quantitativement la fuite protCinique microvascu-
laire induite dans Ic complement. Des rats ont recu des injections intra-
artCrielles d'un colorant fluorescent conjugue a de Ia serum albumine de
rat, et ont subi une dialyse peritonCale avec Cchanges des 15 mm
pendant 3.5 heures. AprCs les echanges contrOles, les rats ont recu du
serum de rat active au zymosan, du solute physiologique, du serum de
rat inactive, ou une endotoxine; d'autres rats ont recu une injection
intrapCritonCale d'endotoxine, d'histamine, de phenylCphrine, ou de
nitroprusside. Le volume de drainage de chaque echange était mesuré,
et les concentrations d'albumine marquees, de protCines totales et
d'urCe ont etC dCterminCes par spectroscopie. Les injections des serums
des rats activCes aux zymosans et les endotoxines (les deux intrapCri-
Received for publication March 17, 1983
and in revised form July 20, 1983
© 1984 by the International Society of Nephrology
tonCales et intra-artCrielles) lesquels peuvent chacun activer Ia voie
alterne du complement, ont produit une augmentation importante des
concentrations de protéines dans le dialysat. En outre, l'histamine, qui
est un vasodilatateur mais qui pourrait Ctre aussi impliquCe comme
mèdiateur dans le système du complement active et/ou dans l'endotoxC-
mie, a Cgalement induit une augmentation des concentrations de
protCine dans le dialysat. Par ailleurs, les mCdicaments qui peuvent
altCrer Ic debit sanguin pCritoneal comme Ic nitroprusside, un vasodila-
tateur, ou la phenylephrine, un vasoconstricteur, n'ont pas modiflC les
concentrations protCiniques du dialysat. Ces donnCes suggèrent que
l'activation de Ia voie alterne du complement pourrait entrainer des
variations de la perte proteinique pendant Ia dialyse peritoneale, et que
dans certaines situations, le contrOle pharmacologique de cc système
pourrait être une possibilité therapeutique importante.
Blood proteins are important in the maintenance of osmotic
balance, as binding sites for drugs and hormones and for
carriage of information (in the form of drugs or hormones) to the
extravascular compartment. During peritoneal dialysis, some
blood protein, including bound substances, may be removed
from the body with the dialysis solution, potentially contribut-
ing to nutritional imbalance [1—3]. Consequently, many investi-
gators have attempted to determine what factors influence
protein loss during peritoneal dialysis [4], including the chemi-
cal composition of the solutions used for dialysis or the pres-
ence of drugs in the solutions [5, 7]. There is considerable
interpatient variability in protein loss associated with peritoneal
dialysis [6, 8], but the factors responsible for this variation have
not been elucidated. They do not appear to relate to variations
in the response of the microcirculation to different solutions [6,
9—11] or to general characteristics of the patients such as age,
sex, and type of dialysis protocol [8].
In addition to chemical factors of dialysis solutions that could
influence protein loss, there are a number of endogenous
substances that can influence macromolecular permeability,
including histamine [12] and activated complement [13]. These
could increase the loss of protein during peritoneal dialysis and
account for some of the observed variability in dialysate protein
concentrations.
Some complications of endstage renal disease could be
associated with these same physiological mechanisms which
will enhance protein permeability. For instance, there is evi-
dence to suggest that the alternative pathway of complement is
deregulated in at least some forms of chronic proliferative
glomerulonephritis [14, 15] and that endotoxin (for example, in
septicemia or peritonitis) may activate the alternative pathway
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Table 1. Animal groups used in this study
Group N Treatment Route of
administration
1 8 Saline, 10 mi/kg Intra-arterial
2 8 Rat plasma, 10 mI/kg Intra-arterial
3 6 None —
4 8 Zymosan-activated rat serum (ZAS),
10 mi/kg
Intra-arterial
5 5 Endotoxin, 4.4 mg/kg Intra-arterial
6 5 Endotoxin, 100 tg/mi serum In vitro analysis
7 7 Endotoxin, 50 j.g/ml in first
exchange (Total dose 1.25 mg/
animal)
Intraperitoneal
8 8 Histamine, (106, io—, and 10 M) Intraperitoneal
9 4 Phenylephrine, (10-v, 106, and
io M) Intraperitoneal
10 6 Nitroprusside, (106, io, and io
M)
Intraperitoneal
of complement [16] and/or produce histamine release [17]. All
of these could lead to an increase in protein permeability. In this
series of experiments we studied whether activated comple-
ment or endotoxin in the blood, or endotoxin or histamine in the
peritoneal fluid would increase protein permeability in the
peritoneal cavity during peritoneal dialysis, both to illuminate
factors which might contribute to interpatient variability in
protein loss and to develop a model for quantitative study of
complement-induced protein leakage during peritoneal dialysis.
Methods
The experimental methods were similar to those previously
reported [7]. Sprague—Dawley rats (230 to 300 g) were anesthe-
tized with subcutaneous pentobarbital (50 mg/kg) and prepared
for peritoneal dialysis. Rectal temperature was monitored and
maintained by a heating pad at 37°C. The left femoral artery was
cannulated for measurement and recording of arterial BP, heart
rate, and for intravascular injections. Tygon tubing (3 mm0.D.,
20 cm long) was inserted into the abdomen through a very small
midline incision. The end of the tubing was placed near the left
rear wall of the peritoneal cavity.
A modified Krebs solution (290 mOsm) was used as the
dialysis solution. This solution contained 113 m NaCI, 11.6
m dextrose, 4.7 mrvt KC1, 1.2 mrvi MgSO4 7 H20, 1.2 mM
KH2PO4, 2.6 mt CaC12 2 H20, and 25 mrvi NaHCO3. The
solution was kept heated to 37°C. It was maintained at a pH of
7.4 with a Pco2 of 40 mm Hg and a P02 of 30 to 40 mm Hg by
bubbling carbon dioxide and nitrogen into the solution prior to
use.
There were multiple dialysis exchanges in each experiment.
The protocol for each exchange was similar to that used by
Brown et al [18] and Miller et al [7]. The dialysis solution (1
mi/lO g of body weight) was instilled into the peritoneal cavity
over 15 sec. There was a 12-mm dwell-time in the peritoneal
cavity, followed by 3 mm for gravity flow drainage of the
dialysis solution into a 50 ml graduated cylinder. After the first
exchange, rat serum albumin which had been conjugated with
fluorescein isothiocynate (FITC-RSA) by the method of Chad-
wick and Fothergill [19] was injected slowly through the femo-
ral artery cannula. The next three exchanges were considered
to be a "washout" of residual protein and equilibration of
FITC-RSA [7]. The next two exchanges (five and six) were
designated the control exchanges. The remaining exchanges
involved an experimental manipulation. Animal groups for this
study are listed in Table 1.
As a source of activated complement, fresh rat serum was
incubated with the reagent complement activator zymosan, as
previously described [20]; 2 U of heparin were added per
milliliter of activated serum. Selected batches of zymosan-
activated serum (ZAS) were assayed by granulocyte aggregom-
etry as previously described [21]. In each batch tested, the
amount of functional C5a (C5a or its desarginine derivative)
equaled or exceeded the activity of pooled normal zymosan-
activated human plasma. ZAS and endotoxin were injected
intravascularly after the control exchanges. Endotoxin, phenyl-
ephrine, and histamine were obtained from Sigma Chemical
Co., St. Louis, Missouri, and nitroprusside from Mallinckrodt,
St. Louis, Missouri. Immediately preceding injection of the first
experimental dialysis solution, either endotoxin, phenyleph-
rifle, histamine, or nitroprusside, in 0.9% saline, was mixed into
the dialysate to give a known concentration. The dialysate was
then injected into the animal.
The volume of each exchange drained from the abdomen was
measured and the dialysate was analyzed for FITC-RSA con-
centration using a fluorometer (Aminco Bowman Spectrophoto,
Savage, Maryland). In some groups the hematocrit was mea-
sured during the control period and the middle of the experi-
mental period. Total protein in the dialysate was measured by
the method of Henry, Sobel, and Segalene [22]. Urea concen-
tration was measured by an autoanalyzer technique. In some
animals, polyacrylamide gel electrophoresis was used to ana-
lyze the dialysate for protein components. All control values for
each protocol represent the mean of the values of the two
exchanges immediately preceding the experimental period.
A separate group of rats was used to determine if endotoxin
in blood could activate complement. Blood was collected from
five rats under ether anesthesia. The serum from each rat was
divided into four aliquots: The first aliquot was incubated for 30
mm with 2 mg zymosan/ml; the second was incubated with 0.1
mg endotoxin/mi; the third was incubated in parallel at 37°C for
30 mm but with a physiological buffered saline (PBS) blank; the
fourth aliquot was diluted with a similar volume of PBS but was
held on ice. In each case, the volume of PBS, zymosan
suspension in PBS, or endotoxin in PBS was one tenth of the
final incubation volume. Each of these samples was then
assayed for C5a by granulocyte aggregometry [21]; human
granulocytes were used as the aggregation target, and serial
dilutions of a batch-prepared human zymosan-activated plasma
were used as the calibration to give data in human ZAP units of
C5a activity.
In our statistical comparisons, Duncan's new multiple range
test [23] with Kramer's [24] correction for differences in group
size was used when group differences were found by analysis of
variance. Student's t test was used for paired comparisons.
Differences were considered statistically significant atP <0.05.
Results
The response to an intra-arterial injection of zymosan-acti-
vated rat serum (ZAS) is compared to the response to normal
rat serum in Figure 1. The amount of labeled rat serum (FITC-
RSA) removed in each exchange reached equilibrium at 45 mm
(the end of the fourth exchange) as evidenced by the plateau of
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Fig. 1. Peritoneal dialysis in rats using 15-mm exchange periods. The
drainage solution was analyzed for the concentration of labeled protein
(FITC-RSA) which had been injected intravascularly at the start of the
experiment. At 90 mm, either 10 mI/kg of zymosan activated rat serum
(ZAS, solid line) or regular rat serum (dashed line) was injected intra-
arterially. FITC-RSA concentration plus I SEM are given for each 15-
mm exchange period.
Table 2. Effect of 4.4 mg/kg, i.a., endotoxin during peritoneal dialysis
in rats (X SEM)
FITC-RSA
ng/ml
MAP
mm Hg
Drainage volume
ml
Control 5.4 1.03 104 4.7 23.5 0.29
Endotoxin
15 mm 10.3 2.72 109 5.9 22.4 0.44
30mm 12.5±2.12a 114±7.7 22.6±0.72
45 mm 12.5 1.32a 112 5.8 23.4 0.43
60 mm 12.0 l.03a 110 5.4 22.1 0.81
75 mm 10.8 l.06a 112 4.3 22.9 0.87
90 mm 9.6 1.12a 111 5.5 22.4 0.58
a The value is significantly different from control values, P < 0.05.
the FITC-RSA concentration at about 2.2 ng/ml at 60 mm. The
injection of ZAS at 90 mm produced a dramatic increase in
FITC-RSA concentration in the dialysate which reached a
maximum at 30 mm after injection. This maximum is approxi-
mately a threefold increase over control values (2.1 0.33
ng/ml at 90 mm vs. 6.8 1.05 nglml at 120 mm). Total dialysate
protein was also measured in this animal group and a similar
increase was observed (13.1 3.7 mgldl at 90 mm vs. 48.0 25
mg/dl at 120 mm). In contrast, unactivated rat serum produced
only a small and slowly developing increase in FITC-RSA
concentration (Fig. 1) or in total protein. In two other groups of
animals, an injection of saline at 90 mm (saline) or no injection
at 90 mm (control) failed to produce an increase in FITC-RSA
by 2 hr after injection (Fig. 2). In all of these groups there was
no significant change in the hematocrit or in the drainage
volume. ZAS did, however, produce a significant drop in BP
from 114 5mm Hg at 90 mm to 101 3.7mm Hg at 120 mm.
BP returned to control values by the end of the experimental
period. Similarly, the heart rate also significantly decreased
from 475 7 bpm during control to 418 16 at 120 mm when
BP was lowest. The heart rate returned to control values by the
end of the experiment. The other treatments had no effect on
BP or heart rate.
An intra-arterial injection of 4.4 mg/kg endotoxin also pro-
duced a significant increase in FITC-RSA dialysate concentra-
tions (Table 2) from a control value of 5.4 1.03 ng/ml to a
maximum of 12.5 2.12 ng/ml at 30 mm after the injection. This
dose of endotoxin had no effect on mean arterial pressure,
hematocrit (45 2.1% before endotoxin, 47 2.5% after
endotoxin), or on drainage volume.
An intraperitoneal injection of endotoxin (group 7) instilled
with the first exchange after the control period, also produced
an increase in dialysate FITC-RSA concentration (Table 3).
However, with this route of administration maximal effect was
observed at the end of the experimental period (105 mm). There
were no significant changes in mean arterial pressure, drainage
volume, or hematocrit (46 0.6% before endotoxin, 46 0.7%
after endotoxin) with the intraperitoneal injection of endotoxin.
A bioassay of the dialysate demonstrated a small but significant
increase in C5a activity (0.28 0.08 U during control vs. 0.37
0.07 U after endotoxin; paired t test). Dialysate and blood
samples were analyzed by polyacrylamide gel electrophoresis.
The largest, most intense band migrated the furthest distance
indicating a small highly charged protein. By comparison with
protein standards, this appeared to be albumin.
Plasma from a separate group of rats was tested by aggrego-
metry for the ability of endotoxin to activate the alternative
pathway of complement. The addition of endotoxin in Hanks'
or in PBS to a stirred granulocyte suspension did not result in
aggregation. The rat plasma incubated with zymosan on the
average generated 69.2 10.2 U (sEM) of C5a. Similarly, the rat
serum incubated with endotoxin generated 51.6 11.5 U of
C5a. The control sera without endotoxin, generated only 2.43
0.11 U of C5a. The iced reserve sample showed 1.68 0.18 U
of C5a activity.
In group 8, after a series of six control exchanges, histamine
was added to the dialysis solution before its instillation. This
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Fig. 2. Peritoneal dialysis in rats. The same protocol was used as in
Figure 1 but at 90 mm there was no injection (control, solid line) or 10
mllkg of normal saline (dashed line) was injected intra-arterially. FITC-
RSA concentration plus or minus 1 SEM are given for each 15-mm
exchange period.
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Table 3. Effect of endotoxin (50 g/m1 added to the 15-mm instillation
solution) during peritoneal dialysis in rats (X sEM)
FITC-RSA
ng/ml
MAP
mm Hg
Drainage volume
ml
Control 4.8 0.74 121 1.3 23.7 3.10
Endotoxin
15 mm 6.1 0.75a 118 2.0 23.0 2.70
30 mm 6.6 0.85a 116 4.7 23.5 2.87
45 mm 7.6 0.74a 115 4.2 23.9 2.82
60mm 8.7±0.73a 115 23.0±2.97
75 mm 9.6 1.40 118 4.8 23.5 2.89
90 mm 11.4 l.93a 119 3.9 23.6 3.11
105 mm 13.8 2.66a 121 3.9 23.5 2.72
The value is significantly different from control values, P < 0.05.
was followed by two washout exchanges and then an exchange
with a higher concentration of histamine. This protocol was
followed for 106, io, and io- M of histamine. Data for this
group are shown in Table 4. Histamine l0 and io M in the
dialysate produced a significant increase in dialysate FITC-
RSA concentration and a similar, significant increase in total
protein. Maximal effect with io M histamine almost doubled
the concentrations of labeled protein (FITC-RSA) and total
protein in the dialysate. However, there were no changes in
mean arterial BP, hematocrit, heart rate, or drainage volumes
produced by this "local" application of histamine.
In groups 9 and 10, the vasoconstrictor phenylephrine or the
vasodilator nitroprusside was placed into the dialysate just prior
to instillation of the solution into the peritoneal cavity. Data for
these groups are shown in Table 5. Phenylephrine and nitro-
prusside did not produce a significant change in FITC-RSA
concentrations. There was also no significant effect on BP,
heart rate, or dialysate volume for either group.
Urea concentrations were used as an index to monitor
alterations in small molecular weight clearance. After the last
control exchange at 90 mm, there was a small but significant
decrease in dialysate urea concentrations in group 1 (intra-
arterial saline injection), group 2 (intra-arterial rat plasma
injection), group 3 (no injection), group 8 (intraperitoneal
histamine, 106, l0, and l0 M), group 9 (intraperitoneal
phenylephrine, l0, 10-6, and i0 M), and group 10 (intraperi-
toneal nitroprusside lQ_6, l0, and i04 M). In general, urea
concentrations continued to decrease in these groups through-
out the experimental period regardless of the treatment. In
contrast, in group 4 (intra-arterial ZAS 10 mI/kg), a paired t test
analysis showed a significant increase in dialysate urea concen-
tration at 120 mm (2.2 1.9 mg/dl during control to 2.6 0.21
mgldl at 120 mm) which corresponded with the time for
maximal dialysate FITC-RSA concentration (Fig. 1). Blood
urea concentration was measured in five groups at the end of
the experiment. It was also significantly elevated for the ZAS
treated group (10.59 1.05 mg/dl) versus the other groups
tested (group 10 = 8.3 0.58 mg/dl; group 3 = 7.8 0.38 mg/dl;
group 1 = 7.5 0.52 mg/dl; and group 2 = 6.0 0.16 mg/dl).
Clearances for urea were also calculated for the exchange at the
end of the experiment just prior to the blood urea determina-
tion. An analysis of variance test for clearances of urea showed
no differences among these groups (group 1 = 0.32 0.04
ml/min; group 2 = 0.52 0.08 ml/min; group 3 = 0.33 0.09
mllmin; group 4 = 0.43 0.05 ml/min; and group 10 = 0.50
0.07 ml/min).
Discussion
During peritoneal dialysis there may be a large and variable
loss of protein [2, 6, 81 which could lead to a loss of vital
hormones as well as produce protein deficiencies. The type of
dialysis protocol, or the individual's age, or sex [8], cannot
explain these large and varied losses. The current study has
examined one set of factors which may be operative during
chronic renal failure (when peritoneal dialysis is indicated) and
which may influence the ability of the peritoneal microcircula-
tion to restrict protein leakage into the peritoneal cavity.
One such mechanism that could lead to increased protein
leakage in the peritoneal cavity could be activation of the
alternative pathway of the complement system. This system has
been shown capable of inducing microvascular leak, probably
through stimulation of granulocytes [13, 20]. Bartlow, Roberts,
and Lewis [14] and Wyatt et al [15] have presented evidence
suggesting that the alternative pathway of complement activa-
tion is not normally regulated in patients with membranoproli-
ferative glomerulonephritis. Although challenged by Moseley
and Wahley [25], this observation, if correct, could lead to
enhanced complement activation in some renal failure patients
and thus to enhanced protein loss during peritoneal dialysis.
In the current series of experiments the alternative pathway
of the complement system was deliberately activated in vitro by
incubation with zymosan to give zymosan activated serum
(ZAS). The ZAS was tested by in vitro aggregometry and found
to have C5a activity (C5a or its desarginine derivative) which is
a major "attack" product of complement activation. Since C3a
is, within seconds, rapidly inactivated in the plasma, we do not
feel that it contributes to the observed responses of ZAS. After
a series of control exchanges, ZAS was injected intravascularly
and produced a marked increase in dialysate protein concentra-
tion (Fig. 1). The concentration of the protein marker, fluores-
cein isothiocynate tagged rat serum albumin, increased from 2.1
0.33 ng/ml in the dialysate during control, to 6.8 1.05 ng/ml
30 mm after the injection of ZAS. Since there was no change in
hematocrit or drainage volume the changes in protein concen-
tration reflect a real increase in protein loss during dialysis. The
response to ZAS is unrelated to the injection technique because
saline injections gave no response (Fig. 2) nor is it related to a
reaction to rat serum (Fig. 1). Serum alone produced only a
trend toward a very slowly developing leak that at its maximum
was not significantly different from the control group, the saline
group (Fig. 2) or to the values during the period before the
injection (Fig. 1, value at 90 mm vs. value at 165 mm).
The increase in dialysate protein concentration that we found
in our experiments with ZAS coincided with a small decrease in
BP. This could be caused by vasodilation or could be accompa-
nied by reflex vasoconstriction. We therefore tested the effects
of local vasodilation (nitroprusside) and local vasoconstriction
(phenylephrine), each of which can alter solute transport during
peritoneal dialysis [261. The administration of concentrations of
nitroprusside which are vasodilatory and may in themselves
lead to protein leakage in rat skeletal muscle [12] only produced
a slight trend (not significant) toward an increase in dialysate
protein (Table 5). These concentrations probably produced
maximal dilation of the peritoneal vasculature [9] that would
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Table 4. Effects of histamine during peritoneal dialysis in the rat (X SEM)
FITC-RSA
ng/ml
Total protein
mg%
MAP
mm Hg
HCT
%
Heart rate
bpm
Drainage volumea
ml
Control exchanges
Histamine, (1O6 Al)
5.3 0.95
5.4 0.98
16.3 4.8
23.0 12.0
126 2.8
125 3.0
49.7 0.4
—
468 10.7
473 10.4
25.5 1.3
25.9 2.4
Histamine, (10 Al) 8.5 1.82" 30.1 8.2" 123 5.6 — 456 12.6 26.3 1.3
Histamine, (10 M) 10.5 2.10" 31.3 8.9b 125 5.3 49.9 0.6 460 28.8 24.3 2.3
a The injection volume was 25.6 1.2 ml.
b The value is significantly different from control, P < 0.05.
Table 5. Effect of intraperitoneal phenylephrine and nitroprusside
during peritoneal dialysis in the rat (X SEM)
FITC-
RSA
ng/ml
MAP
mm Hg
Heart
rate
bpm
Drainage
volumea
ml
Group 9 (N = 4)
Control exchange 3.0 0.4 119 24 402 4 22.5 2.38
Phenylephrine,(I0 M) 2.9 0.4 117 17 404 16 22.5 1.73
Phenylephrine,
(106 M) 2.5 0.3 122 18 398 39 21.5 2.64
Phenylephrine,(10 M) 2.3 0.3 136 20 375 57 22.2 2.63
Group 10 (N = 6)
Controlexchange 5.3 1.1 124 8 435 11 23.5 2.5
Nitroprusside,
(10-6 M) 5.5 1.6 124 7 429 10 24.5 2.2
Nitroprusside,(10 M) 6.4 3.3 126 4 420 11 24.7 3.1
Nitroprusside,(I0 M) 6.5 2.2 106 12 399 29 24.0 1.6
a The injection volume was 22.8 1.50 ml for group 9 and 24.5 2.2
ml for group 10.
likely increase microvascular pressure. Since this did not lead
to protein leakage, any vasodilation in the peritoneum that
might be produced by ZAS (10 mi/kg) probably does not have
any substantial effect on protein permeability. The administra-
tion of concentrations of phenylephrine which are vasoconstric-
tor and could alter capillary exchange in the peritoneal cavity
also did not significantly affect FITC-RSA concentrations or
systemic BP (Table 5). Thus, the small decrease in systemic
pressure produced by ZAS (10 mi/kg) probably does not explain
its ability to increase dialysate protein concentrations.
We have previously shown in patients with chronic renal
failure, that intraperitoneal nitroprusside produces dramatic
increases in total protein concentration in the dialysate [6]. Yet
we found in our current rat peritoneal dialysis experiments only
minimal (and not significant) increases in FITC-RSA (albumin)
concentrations produced by nitroprusside (Table 5). The reason
for this discrepancy is not apparent. It is possible that besides
the obvious species and anesthetic differences, chronic renal
failure itself influences the effect of nitroprusside. Other investi-
gators [27] have shown that patients with chronic renal failure
have increased macromolecular transport. Alternatively, Nolph
et al [4] have shown that the response to nitroprusside is very
time dependent (protein concentration at a 60-mm dwell was
almost three times that at 15 mm). Thus, with the short
exchange periods used in the rat experiments in this study (15
mm), there may have been insufficient time to observe a
significant nitroprusside response in rats. The observations of a
substantial effect by histamine over the same exchange time
could be due to the greater efficacy of histamine [12] in
producing macromolecular leakage.
Because there are observations that peritonitis may increase
dialysate protein concentrations [1, 28, 29], the possible influ-
ence of endotoxin was examined. In our in vitro experiment we
demonstrated that zymosan and endotoxin were both effica-
cious activators of C5a activity. In one group of peritoneal
dialysis experiments, a dose of endotoxin was chosen for
intravascular administration to mimic a low grade septicemia.
Endotoxin produced an effect similar to ZAS. FITC-RSA
concentration increased from 5.4 1.03 ng/ml at 90 mm to 12.5
2.12 ng/ml at 120 mm (Table 2). BP and dialysate volumes
were constant and thus could not account for this effect. In
another group of animals an intraperitoneal injection of endo-
toxin also produced an increase in dialysate protein concentra-
tions (Table 3). Since the time course was considerably slower
in this group for maximal effect, (30 mm for maximal effect after
intra-arterial injections vs. 120 mm after intraperitoneal injec-
tions), systemic absorption of the endotoxin may be necessary
to activate complement. This and/or a dilutional effect of the
dialysate could also explain why we observed only a small but
significant increase in C5a-like activity in the dialysate of the
animals injected intraperitoneally with endotoxin and a large
increase in serum C5a activity after in vitro incubation of blood
with endotoxin. Alternatively, resident macrophages or granu-
locytes that may have been recruited into the peritoneal cavity
could have elaborated proteases which degrade CSa and C5a
desarginine.
The similarity between the responses to ZAS and endotoxin
implies that either or both could contribute to the problem of
loss of protein during peritoneal dialysis. Heflin and Brigham
[30] have also found in the lung that endotoxin produces protein
leakage. In fact, Glauser et al [17] and Fearon et al [16] have
presented evidence which suggests that endotoxin may act
through the alternative pathway of complement and/or by
release of histamine from mast cells. Thus, we might expect a
large local release of histamine to produce the same response as
endotoxin or ZAS. This was tested by mixing the histamine into
the dialysate just prior to instillation in the peritoneal cavity.
Since intraperitoneal histamine produced a concentration-de-
pendent increase in FITC-RSA and total protein concentration
(Table 4), release of histamine as a mechanism for the effect of
endotoxin or ZAS is a possibility. In fact, other investigators
[31] have identified a role of histamine in the spasmogenic effect
of C5a-desarginine.
The similarity in the percentage increase after the injection of
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histamine (Table 4) and after ZAS for both protein determina-
tions (total protein and FITC-RSA) suggest that much of the
protein leakage into the peritoneal cavity is in the form of
albumin. This was confirmed by gel electrophoresis studies on
the protein in the dialysate. Our additional observations that
urea clearance did not change with ZAS although blood urea
concentration increased, suggests that ZAS has primarily af-
fected mechanisms responsible for macromolecular leakage.
Our data thus demonstrate that complement activation, endo-
toxinemia, or peritonitis may enhance protein losses during
peritoneal dialysis. These effects do not appear to be related to
general hemodynamic changes or to local vasodilation or vaso-
constriction in the peritoneal cavity. Our data also demonstrate
that conditions which might be expected to release histamine in
the tissues of the peritoneal cavity (allergic reactions, inflamma-
tion, septicemia, drugs, and so forth) may also increase protein
losses during peritoneal dialysis. The presence of these addi-
tional and possibly subtle factors (that is, systemic endotoxin
without BP change or an intraperitoneal exposure to endotoxin
during dialysis) which may increase protein loss during perito-
neal dialysis may explain some of the large variation in protein
loss found by other investigators. Since we demonstrated that
endotoxins incubated with serum activates the alternative path-
way of complement and C5a activity is also found in the
dialysate after intraperitoneal endotoxin, complement activa-
tion may be involved in protein loss during peritonitis. Whether
or not enough complement activation occurs in uncomplicated
peritoneal dialysis to be a major contributor to protein loss
remains to be determined.
Finally, we have developed a model which allows reproduc-
ible measures of complement-induced macromolecular leakage.
This model should be of use in studying physiologic and
pharmacologic manipulation of a variety of vascular or immu-
nological insults during peritoneal dialysis.
Reprint requests to Dr. F. N. Miller, Department of Physiology,
Health Sciences Center, University of Louisville, Louisville, Kentucky
40292, USA
References
1. BLUMENKRANTZ MJ, SCHMIDT RW: Managing the nutritional
concerns of the patient undergoing peritoneal dialysis, in Peritoneal
Dialysis, edited by NOLPH KD, The Netherlands, Martinus Nijhoff
Publishers, 1981, pp. 275—308
2. GOTLOIB L, CRASSWELLER P, RODELLA H, OREOPOULOS DG,
ZELLERMAN G, OGILVIE R, HUSDAN H, BRANDES L, VAS 5:
Experimental model for studies of continuous peritoneal dialysis in
uremic rabbits. Nephron 31:254—259, 1982
3. PENNISI AJ, WANG M, KOPPLE JD: Effects of protein and amino
acid diets in chronically uremic and control rats. Kidney mt 13:472—
479, 1978
4. N0LPH KD, GHODS AJ, BROWN P, VANSTONE J, MILLER FN,
WIEGMAN DL, HARRIS PD: Factors affecting peritoneal dialysis
efficiency. Dial Trans 6:52—63, 1977
5. RUBIN J, NOLPH KD, ARFANIA D, MILLER FN, WIEGMAN DL,
JOSHUA IG, HARRIS PD: Clinical studies with non-vasoactive
peritoneal dialysis solution. J Lab Clin Med 93:910—915, 1979
6. MILLER FN, NOLPH KD, HARRIS PD, RUBIN J, WIEGMAN DL,
JOSHUA IG, TWARDOWSKI JB, GH0D5 AJ: Microvascular and
clinical effects of altered peritoneal dialysis solutions. Kidney mt
15:630—639, 1979
7. MILLER FN, NOLPH KD, SORKIN MI, GLOOR HJ: The influence of
solution composition on protein loss during peritoneal dialysis.
Kidney mt 23:35—39, 1983
8. BLUMENKRANTZ MJ, GAHL GM, KOPPLE JD, KAMDAR AV, JONES
MR, KE5SEL M, COBURN JW: Protein losses during peritoneal
dialysis. Kidney mt 19:593—602, 1981
9. MILLER FN, WIEGMAN DL, JOSHUA IG, NOLPH KD, RUBIN J:
Effects of vasodilators and peritoneal dialysis solution on the
microcirculation of the rat cecum. Proc Soc Exp Biol Med 161:605—
608, 1979
10. JAUCI-IEM JR, MILLER FN, HARRIS PD, WIEGMAN DL, JOSHUA 1G
Interaction of acetate, lactate, and osmolality on contraction of
mesenteric arteries. Microcirculation 1:37—54, 1981
11. MILLER FN, NOLPH KD, JOSHUA IG, WIEGMAN DL, HARRIS PD:
Hyperosmolality, acetate and lactate. Dilatory factors during pen-
toneal dialysis. Kidney mt 20:397—402, 1981
12. MILLER FN, JOSHUA IG, ANDERSON GL: Quantitation of vasodila-
tor induced macromolecular leakage by in vivo fluorescent micros-
copy. Microvasc Res 24:56—67, 1982
13. HAMMERSCHMIDT DE, HARRIS PD, WAYLAND JH, CRADDOCK PR,
JACOB HS: Complement-induced granulocyte aggregation in vivo.
AmJPathol 102:146—150, 1981
14. BARTLOW BG, ROBERTS JL, LEWIS EJ: Nonimmunoglobulin C3
activating factor in membranoproliferative glomerulonephritis. Kid-
ney mt 15:294—302, 1979
15. WYATT RJ, MCADAMS AJ, FORRISTAL J, SNYDER J, WEST CD:
Glomerular deposition of complement-control proteins in acute and
chronic glomerulonephritis. Kidney mt 16:505—512, 1979
16. FEARON DT, RUDDY 5, SCHUR PH, MCCABE WR: Activation of
the properidin pathway of complement in patients with gram-
negative bacteremia. N Engl J Med 292:937—945, 1975
17. GLAUSER FL, PALMER J, CECC0NI 5, SCHOOLCRAFT W, WELLS I,
NOVEY H, EGAN P, SMELTZER D: The effect of endotoxin on the
mast cell c'AMP system. Ann Allergy 38:104—107, 1977
18. BROWN EA, KLIGER AS, GOFFINET J, FINKELSTEIN FO: Effect of
hypertonic dialysate and vasodilators on peritoneal dialysis clear-
ances in the rat. Kidney mt 13:271—277, 1978
19. CHADWICK CS, FOTHERGILL JE: Fluorochromes and their conjuga-
tion with proteins, in Fluorescent Protein Tracing, edited by NARIN
RC, Edinburgh, E & S Livingstone, 1962, pp 4—30
20. CRADDOCK PR, HAMMERSCI-IMIDT DE, DALMASSO AP, WHITE JG,
JACOB HS: Complement (CSa) induced granulocyte aggregation in
vitro: a possible mechanism of complement-mediated leukostasis
and leukopenia. J Clin Invest 60:260—264, 1977
21. HAMMERSCHMIDT DE, BOWERS TK, LAMMI-KEEFE CJ, JACOB
HS, CRADDOCK PR: Granulocyte aggregometry: a sensitive tech-
nique for the detection of C5a and complement activation. Blood
15:898—902, 1980
22. HENRY RJ, SOBEL C, SEGALENE M: Turbidometric determination
of proteins with sulfosalicyclic and trichloroacetic acids. Proc Soc
Exp Biol Med 92:748—751, 1956
23. DUNCAN DB: Multiple range and multiple F tests. Biometrics 11:1—
42, 1955
24. KRAMER CY: Extension of multiple range tests to group means with
unequal number of replications. Biometrics 12:307—3 10, 1956
25. MOSELEY HL, WHALEY K: Control of complement activation in
membranes and membranoproliferative glomerulonephnitis. Kidney
mt 17:535—544, 1980
26. MAHER TF: Pharmacological manipulations of peritoneal transport,
in Peritoneal Dialysis, edited by NOLPH KD, The Netherlands,
Martinus Nijhoff Publishers, 1981, pp 213—239
27. RUBIN J, RUST P, BROWN P, POPOVICH RP, NOLPH KD: A
comparison of peritoneal transport in patients with psoriasis and
uremia. Nephron 29:185—189, 1981
28. OREOPOULOS, DG: Chronic peritoneal dialysis in hospital. Contrib
Nephrol 17:5—9, 1979
29. RUBIN J, MCFARLAND 5, HELLEMS EW, BOWER JD: Peritoneal
dialysis during peritonitis. Kidney mnt 19:406—464, 1981
30. HEFLIN AC JR, Brigham KL: Prevention by granulocyte depletion
of increased vascular permeability of sheep lung following endotox-
emia. J Clin Invest 68:1253—1260, 1981
31. SORGENFREI J, DAMERAU B, VOGT W: Role of histamine in the
spasmogenic effect of the complement peptides C3a and C5a-des
Arg (Classical anaphylatoxin). Agents Actions 12:118—121, 1982
